{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:45Z","timestamp":1792718325027,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Systemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines. The use of JAKi in SJIA or macrophage activation syndrome (MAS) has only been described in a limited number of case reports. In this study, we aimed to assess the efficacy and potential adverse effects of JAKi in SJIA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with SJIA who received JAKi and underwent at least one assessment of efficacy and safety after JAKi initiation were eligible for this study. Data were collected retrospectively from inpatient or outpatient medical records at JAKi initiation, at 1, 3, 6, 9, and 12 months, after disease flare, after JAKi discontinuation, or at the last follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten patients with SJIA were included in the study. At the start of JAKi treatment, all patients presented with active disease; five showed variable adverse effects secondary to glucocorticoids. Seven patients received tofacitinib (one later switched to ruxolitinib). Of these, only two patients showed a complete response of persistent arthritis associated with tocilizumab; tofacitinib was used without a biological DMARD only in two patients, together with MTX, showing a partial response; three patients were nonresponders. Four patients with SJIA-related MAS or persistent hyperferritinemia were treated with ruxolitinib. Ruxolitinib allowed a good response on MAS parameters in three of them. All these four patients required an adjunction or switch to canakinumab later. The median decrease in the daily glucocorticoid dose between JAKi initiation and the last follow-up was 90.6% in patients with complete remission and 77.4% in other patients. Three patients discontinued glucocorticoid treatment after the introduction of JAKi. Severe adverse events, notably serious infection or thrombosis, were not observed during JAKi treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>JAKi may be an alternative or adjuvant agent for SJIA patients, especially in those with persistently active disease, glucocorticoid-related adverse reactions, or SJIA-MAS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1134312","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:01:31Z","timestamp":1682028091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["JAK inhibitors in systemic juvenile idiopathic arthritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Tingyan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood-2015-12-688960","article-title":"Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice","volume":"127","author":"Sepulveda","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-021-00534-0","article-title":"Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis","volume":"19","author":"Chi","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3899\/jrheum.150997","article-title":"The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013","volume":"43","author":"Janow","year":"2016","journal-title":"J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis","author":"Gillard","year":"","journal-title":"Rheumatology (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","article-title":"Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis: refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease","volume":"47","author":"Erkens","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi","year":"2020","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40744-022-00496-z","article-title":"Sequential tocilizumab and tofacitinib treatment for systemic juvenile idiopathic arthritis: a case report","volume":"10","author":"Zhang","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","volume":"81","author":"Bader-Meunier","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the Aicardi-Goutieres syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1134312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:01:33Z","timestamp":1682028093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1134312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":18,"alternative-id":["10.3389\/fped.2023.1134312"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1134312","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"article-number":"1134312"}}